Shockwave Medical (Nasdaq:SWAV) announced today that it completed its $147 million acquisition of Neovasc. In January, Shockwave announced an agreement to acquire all of the issued and outstanding common shares of Neovasc. The company paid $27.25 per share upfront by way of a statutory plan of arrangement. The deal has an enterprise value of … [Read more...] about Shockwave Medical completes Neovasc acquisition

Shockwave Medical (NSDQ:SWAV) this week announced it signed an agreement to acquire all of the issued and outstanding common shares of Neovasc (NSDQ:NVCN). Neovasc enrolled its first patient in a clinical trial studying the Neovasc Reducer in January 2022. The company designed the device to reduce angina symptoms in people with refractory … [Read more...] about Shockwave Medical to acquire Neovasc for up to $147M